Table 1 Patient cohort, clinical information, and cell enumeration.

From: Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

No. Sex Age Type Treatment Time Biopsy? CTCs Vol. CTCs/mL (PDL1 + ) (PDL1−) (UD) WBCs/mL
P01 M 61 squamous Pembrolizumab Pre Y 47 6 7.83 4.83 2.83 0.16 60
P02 M 59 adeno. Pembrolizumab Pre 35 6 5.83 5 0.83 6
P03 F 77 adeno. Ipilimumab, Nivolumab Pre 44 8 5.5 0 5.5 17
P04 M 67 adeno. Nivolumab Pre 28 6 4.67 2.83 1.83 56
P05 F 59 adeno. Pembrolizumab Pre Y 19 6 3.17 1.5 1.66 18
P06 F 61 adeno. Erlotinib Pre Y 24 8 3 2 1 1
P07 F 77 adeno. Pembrolizumab Pre Y 19 9 2.11 0.33 1.77 11
P08 F 87 adeno. Ipilimumab, Nivolumab Pre 16 8 2 0 2 93
P09 F 91 adeno. Ipilimumab, Nivolumab Pre 10 8 1.25 0 1.25 18
P10 M 65 adeno. Ipilimumab, Nivolumab Pre 3 8 0.38 0 0.38 11
P11 M 66 adeno. Ipilimumab, Nivolumab Pre 2 6 0.33 0.16 0.16 19
P12 F 60 adeno. Ipilimumab, Nivolumab Pre 2 7 0.29 0 0.29 27
P13 M 65 adeno. Pembrolizumab Pre 1 6 0.17 0 0.17 23
P14 M 64 adeno. Pembrolizumab Pre 1 9.8 0.1 0.1 0 2
P15 F 75 squamous Ipilimumab, Nivolumab Pre 0 6 0 0 0 13
P16-1 M 62 squamous Avelumab Pre 20 6 3.33 3 0 0.33 10
P16-2      On treatment 5 8 0.62 0.5 0.12 10
P16-3      On treatment 11 6 1.83 1.83 0 5.3
P16-4      On treatment 31 8 3.87 3.5 0.12 0.25 14.9
P16-5      On treatment 6 6 1 1 0 10
P17 M 78 adeno. Pembrolizumab Pre 3 8 0.38 0.125 0.25 13
P18 M 82 adeno. Ipilimumab, Nivolumab After 1st dose 1 6 0.17 0.17 0 19
P19-1 M 69 squamous Pembrolizumab After 1st dose 4 6 0.67 0 0.67 9.33
P19-2      On treatment 6 8 0.75 0.5 0.25 3.75
P19-3      On treatment 1 8 0.12 0 0.12 17.62
P19-4      On treatment 58 6 9.67 1.33 8.33 16.83
P19-5      On treatment 8 8 1 0.62 0.25 0.12 7.5
P19-6      After treatment 1 6 0.17 0.17 0 20.5
P20 M 76 adeno. Pembrolizumab On treatment 43 6 7.16 0.16 6.83 0.16 30
P21 F 51 adeno. Avelumab On treatment 24 6 4 0.5 3.5 20
P22 M 74 squamous Pembrolizumab On treatment 2 8 0.25 0 0.25 5
HD01 F 57 Healthy 2 4 0.5 14
HD02 M 55 Healthy 5 4 1.25 30.75
HD03 M 20 Healthy 0 2 0 18.5
HD04 M 23 Healthy 2 6 0.33 12
HD05 M 35 Healthy 5 6 0.83 19.3
HD06 F 69 Healthy 6 6 1 17.3
HD07 F 77 Healthy 2 6 0.33 27.6
HD08 F 41 Healthy 4 6 0.66 21.3
HD09 M 69 Healthy 1 6 0.16 29
HD10 F 60 Healthy 3 6 0.5 13.83
  1. 31 patient blood samples and 10 healthy donor samples were processed through Vortex technology. These 31 samples were collected from 22 different NSCLC patients: 5 squamous, 17 adenocarcinoma, with 17 blood samples collected pre-treatment, 2 after the first cycle, and 11 during the treatment. 15 samples had ≥10 CTCs and were considered for further study, with 4 of them having a biopsy of the primary tumor available. (PDL1+), (PDL1−) and (UD) respectively indicate the number of CTCs per mL that are either identified as PD-L1 positive, PD-L1 negative or undetermined.